Mary Crowley Cancer Research Centers

Dallas, Texas 75251

2 studies enrolling now · 42 studies all time

What they study most

APC Gene Mutation, AXIN1 Gene Mutation, Advanced Breast Cancer, Advanced Cancer, Advanced Cancers, Advanced Malignancies, Advanced Melanoma, Advanced Non-small Cell Lung Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Breast Cancer, Cancer

Studies at this site

• A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies — Recruiting now
• AMT-116 in Patients With Advanced Solid Tumors — Recruiting now
• Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors — Recruiting now
• A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors — Running, not enrolling
• Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) — Running, not enrolling
• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) — Running, not enrolling
• A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation — Stopped early
• A Trial of Vigil for Participants With Ovarian Cancer — Running, not enrolling
• A Trial of FANG™ Vaccine for Participants With Ovarian Cancer — Completed
• Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma — Completed
• A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer — Completed
• Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC — Completed
• A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) — Stopped early
• MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors — Completed
• Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma — Completed
• A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma — Completed
• Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer — Completed
• Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases — Stopped early
• Salvage Ovarian FANG™ Vaccine + Bevacizumab — Completed
• Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC — Stopped early
• Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer — Completed
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET — Completed
• Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer — Stopped early
• A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) — Completed
• Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer — Stopped early
• CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) — Completed
• Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma — Completed
• Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers — Completed
• Salvage Ovarian FANG™ Vaccine + Carboplatinum — Completed
• Phase II FANG™ in Advanced Melanoma — Stopped early
• Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors — Completed
• Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer — Completed
• Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer — Withdrawn before enrolling
• Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) — Completed
• Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer — Completed
• A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients — Stopped early
• A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies — Completed
• A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors — Completed
• Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy — Completed
• Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer — Withdrawn before enrolling
• Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma — Completed
• A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors — Completed